title: High serum fasting peptide YY (3-36) is associated with obesity-associated insulin resistance and type 2 diabetes.
abstract: We studied whether serum fasting levels of active form of peptide YY (PYY), PYY(3-36), are associated with obesity and related phenotypes. The study population consisted of 428 patients with coronary artery disease and diagnosed type 2 diabetes and 440 patients with coronary artery disease but without evidence of diabetes from the ARTEMIS study. The patients were recruited from the consecutive series of patients undergoing coronary angiography in the Oulu University Hospital. The patients without diabetes underwent a 2-hour oral glucose tolerance test. PYY(3-36) levels were analyzed by human PYY(3-36) specific radioimmunoassay. Result suggested that when PYY(3-36) tertiles were considered, high serum fasting PYY(3-36) concentration was associated with high body mass index, waist circumference, hemoglobin A1c, fasting blood glucose, leptin, triglyceride (p for all p ≤ 0.001), serum insulin (p=0.013) and with a low high-density lipoprotein cholesterol (p=0.004) concentrations in the analyses adjusted for age, sex and study group. The link high PYY(3-36)-high insulin level was evident in subjects with normal glucose tolerance (p<0.05). The prevalence of diabetes was 72%, 46% and 30% in the highest, medium and lowest PYY(3-36) tertile (p<0.001). The PYY(3-36) concentrations (after adjustment for age, sex and body mass index) were higher in type 2 diabetics compared to subjects with impaired fasting glucose, impaired glucose tolerance and normal glucose tolerance (p<0.001 for trend). In conclusion, fasting PYY(3-36) concentrations in type 2 diabetic subjects are high. Although high PYY(3-36) is strongly linked to obesity and associated insulin resistance, the relation between PYY(3-36) and type 2 diabetes is independent of body fatness.
authors.affiliation: Institute of Clinical Medicine, Department of Internal Medicine, Finland; Biocenter Oulu, University of Oulu and Clinical Research Center of Oulu University Hospital, Finland. olavi.ukkola@oulu.fi
authors.forename: Olavi H
authors.initials: OH
authors.lastname: Ukkola
authors.forename: Veli-Pekka
authors.initials: VP
authors.lastname: Puurunen
authors.forename: Olli-Pekka
authors.initials: OP
authors.lastname: Piira
authors.forename: Jarkko T
authors.initials: JT
authors.lastname: Niva
authors.forename: E Samuli
authors.initials: ES
authors.lastname: Lepojärvi
authors.forename: Mikko P
authors.initials: MP
authors.lastname: Tulppo
authors.forename: Heikki V
authors.initials: HV
authors.lastname: Huikuri
mesh_terms: D000368:Aged; D001786:Blood Glucose; D001794:Blood Pressure; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D003324:Coronary Artery Disease / Q000209:etiology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000209:etiology / Q000503:physiopathology; D005215:Fasting / Q000097:blood; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D009765:Obesity / Q000150:complications*; D019894:Peptide YY / Q000097:blood*
chemical_list: D001786:Blood Glucose; D007328:Insulin; D019894:Peptide YY; D002784:Cholesterol